Partial
Mostly Aligned
Patient Risk:
Moderate
Summary
Several statements regarding mechanism, vasodilation, and key contraindications/interactions are supported. However, multiple dosing/usage assertions (e.g., “once daily standard clinical use”) and broader efficacy framing are not supported by the provided label excerpts, and the response appears to conflate tadalafil broadly with ADCIRCA without clear label support for formulation/dosing.
Category Scores
Accurate Statements
Tadalafil is used to treat pulmonary arterial hypertension.
ADCIRCA is indicated for treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability. (1.1 Pulmonary Arterial Hypertension)
Tadalafil works as a phosphodiesterase type 5 (PDE5) inhibitor.
Tadalafil is an inhibitor of PDE5. (12.1 Mechanism of Action)
Tadalafil helps relax blood vessels.
Inhibition of PDE5 increases cGMP resulting in relaxation of pulmonary vascular smooth muscle cells and vasodilation of the pulmonary vascular bed. (12.1 Mechanism of Action)
Tadalafil improves blood flow in the lungs.
Label describes vasodilation of the pulmonary vascular bed and relaxation of pulmonary vascular smooth muscle (mechanism for pulmonary vasculature). (12.1 Mechanism of Action)
The interaction between tadalafil and nitrates or certain blood-pressure–lowering combinations can cause a dangerous drop in blood pressure.
ADCIRCA potentiates the hypotensive effect of nitrates and is contraindicated with organic nitrates. (4.1 Concomitant Organic Nitrates); PDE5 inhibitors may be mild systemic vasodilators and coadministration studies show blood pressure reductions with selected antihypertensives. (7.3 Antihypertensives)
People who take nitrates (for chest pain) are usually advised against using tadalafil.
ADCIRCA is contraindicated in patients using any form of organic nitrate; do not use nitrates within 48 hours of the last dose. (4.1 Concomitant Organic Nitrates)
People taking certain blood-pressure–lowering combinations are usually advised against using tadalafil.
Coadministration with GC stimulators such as riociguat is contraindicated. (4.2 Concomitant Guanylate Cyclase (GC) Stimulators); Additive blood pressure lowering may be anticipated with alpha-blockers; clinical pharmacology studies evaluated antihypertensives. (7.2 Alpha-Blockers; 7.3 Antihypertensives)
Unsupported Statements
Tadalafil is an option among disease-targeted therapies for pulmonary arterial hypertension.
The provided excerpts do not describe “disease-targeted therapies” or position tadalafil within a category beyond the indication statement in 1.1.
Tadalafil is taken by mouth once daily for pulmonary arterial hypertension in standard clinical use.
No dosing frequency/route is provided in the supplied label excerpts.
The exact dose of tadalafil should be based on a prescriber’s instructions for the individual patient.
No label text about individualized dosing selection is provided in the supplied excerpts.
A practical safety concern with tadalafil is avoiding certain combinations that can cause dangerous low blood pressure.
The label excerpt supports hypotension/vasodilation and specific contraindications (nitrates; GC stimulators) and blood pressure lowering with other agents, but the statement is overgeneral and not specifically worded as a “practical safety concern” in the excerpts.
Contradictions
Low
AI Statement
Tadalafil is taken by mouth once daily for pulmonary arterial hypertension in standard clinical use.
Label Reference
No direct contradiction can be confirmed from the provided excerpts.
Important Omissions
Dose (including frequency), titration, and specific administration instructions for ADCIRCA/then-tadalafil in PAH.
Importance:
Moderate
Contraindications beyond organic nitrates and GC stimulators (e.g., boxed warnings, if any) and other warnings/precautions text not included in the provided excerpts.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Main safety-relevant interactions (organic nitrates contraindication; GC stimulator contraindication; hypotension risk) are partially reflected, but the response includes unsupported/generalized dosing and safety framing. Missing label dosing/administration details could affect safe interpretation.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Mostly Aligned
Primary Issue
Unsubstantiated dosing/frequency (“once daily”) and generalized safety statements that are not directly supported by the provided label excerpts.
Suggested Improvement
Remove or replace unsupported dosing and generalized “dangerous low blood pressure” phrasing with label-supported specifics (e.g., contraindication with organic nitrates; contraindication with GC stimulators such as riociguat; hypotension/vasodilatory properties). Support dosing claims with the label section that explicitly states route and frequency.